The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1248
November 20, 2006
View Complete Issue         Table of Contents 2019 
Posaconazole (Noxafil) for Invasive Fungal Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Posaconazole (Noxafil) for Invasive Fungal Infections
November 20, 2006 (Issue: 1248)
Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus infections in severely immunocompromised patients...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Posaconazole (Noxafil) for Invasive Fungal Infections
Article code: 1248a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.